Macimorelin - COSCIENS Biopharma
Alternative Names: AEZS-130; ARD-07; D-87575; EP-01572; EP-1572; Ghryvelin; JMARD-07; JMV-1843; Macimorelin acetate; Macrilen; SolorelLatest Information Update: 29 Aug 2024
At a glance
- Originator AEterna Zentaris Inc
- Developer Consilient Health; COSCIENS Biopharma; Novo Nordisk; University of Queensland
- Class Amides; Carboxylic acids; Diagnostic agents; Indoles; Oligopeptides; Small molecules
- Mechanism of Action Ghrelin receptor agonists; Ghrelin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Somatotropin deficiency
Highest Development Phases
- Marketed Somatotropin deficiency
- Phase II Cachexia
- Preclinical Amyotrophic lateral sclerosis
Most Recent Events
- 27 Aug 2024 Efficacy and adverse events data from the phase III DETECT AEZS-130-P02 trial Somatotropin deficiency released by COSCIENS Biopharma
- 06 Aug 2024 AEterna Zentaris Inc is now called COSCIENS Biopharma
- 13 Jun 2024 AEterna Zentaris completes a phase III DETECT trial for Somatotropin deficiency (Diagnosis, In children, In adolescents) in USA, Armenia, Georgia, Poland, Italy, Slovenia, Germany, Romania, Serbia, Slokavia and Turkey (PO) (NCT04786873) (EudraCT2018-001989-42)